Two kinds of pain

Pain can be sub-catogarized in two “well recognized” types of Pain:

  • Nociceptive Pain, perceived as a response to a stimuli internal or external to the body (damage to the body, nausea, tumors…) and interpreted by the Central Nervous system which sends a pain signal to the brain.
  • Neuropathic Pain, arising from malfunction or damage directly suffered by the peripheral and/or central nervous system. Damages can result from various factors (Multiple Sclerosis, chemotherapy, diabetes…). Neuropathic pain affects about 7 to 10% of worldwide population.

Most of Pain killer have been developed between 100 and 50 years ago. In our current era, there is a huge demand for non-addictive (non-opioid) pain treatments.

Neuroservices-Alliance, your Pain drug discovery platform expert

Thanks to the crossed expertise of our expert platforms, we offer a wide combination of assays to help our clients achieve their pain preclinical drug discovery goals.

We offer in vitro and in vivo assays in non-human (neuronal cultures, spinal cord slices,…) and human tissues (native human sensory neurons or iPSC-derived sensory neurons). 

For more in-depth details on our capabilities, watch our short webinar below in which Bruno Buisson, President and CSO of Neuroservices-Alliance, presents the expertise of Neuroservices-Alliance platforms:

Are you currently working on a program targeting pain? Please contact us and we will gladly discuss with you how we can be a true asset to your pain preclinical drug discovery program.

Bob Petroski, PhD
CSO in vitro cell
electrophysiology
Bruno Buisson, PhD
Co-Founder, President & CSO
Jeffrey Hubbard, PhD
CSO in vitro slice
electrophysiology
Andre GHETTI, PhD
CEO
ANABIOS
Najah ABI-GERGES, PhD
VP of R&D
ANABIOS
Julien Allard, PhD
in vivo spinal cord
electrophysiology expert
Alain ESCHALIER, MD, PhD, PharmD
Pain Expert
EVA.CR
Fabrice TROVERO,PhD
GM & Behavioral Pharmacologist
KEY-OBS
Jean-Charles BIZOT, PhD
CEO & Behavioral Pharmacologist
KEY-OBS